PL1727545T3 - Zastosowanie pochodnych N-piperydyny do leczenia patologii neurodegeneracyjnych - Google Patents

Zastosowanie pochodnych N-piperydyny do leczenia patologii neurodegeneracyjnych

Info

Publication number
PL1727545T3
PL1727545T3 PL05715443T PL05715443T PL1727545T3 PL 1727545 T3 PL1727545 T3 PL 1727545T3 PL 05715443 T PL05715443 T PL 05715443T PL 05715443 T PL05715443 T PL 05715443T PL 1727545 T3 PL1727545 T3 PL 1727545T3
Authority
PL
Poland
Prior art keywords
treatment
piperidine derivatives
neurodegenerative pathologies
pathologies
neurodegenerative
Prior art date
Application number
PL05715443T
Other languages
English (en)
Inventor
Gianfranco Merizzi
Original Assignee
Medestea Res & Production S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medestea Res & Production S P A filed Critical Medestea Res & Production S P A
Publication of PL1727545T3 publication Critical patent/PL1727545T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05715443T 2004-03-01 2005-02-22 Zastosowanie pochodnych N-piperydyny do leczenia patologii neurodegeneracyjnych PL1727545T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000124A ITTO20040124A1 (it) 2004-03-01 2004-03-01 Nuovi impieghi in terapia di derivati di n-piperidina particolarmente per il trattamento di patologie neurodegenerative
EP05715443A EP1727545B1 (en) 2004-03-01 2005-02-22 Use of n-piperidine derivatives for the treatment of neurodegenerative pathologies
PCT/EP2005/001818 WO2005084677A1 (en) 2004-03-01 2005-02-22 Use of n-piperidine derivatives for the treatment of neurodegenerative pathologies

Publications (1)

Publication Number Publication Date
PL1727545T3 true PL1727545T3 (pl) 2013-01-31

Family

ID=34917559

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05715443T PL1727545T3 (pl) 2004-03-01 2005-02-22 Zastosowanie pochodnych N-piperydyny do leczenia patologii neurodegeneracyjnych

Country Status (14)

Country Link
US (1) US8461186B2 (pl)
EP (1) EP1727545B1 (pl)
JP (1) JP2007525530A (pl)
KR (1) KR101244799B1 (pl)
CN (1) CN1946400B (pl)
AU (1) AU2005218739A1 (pl)
BR (1) BRPI0507817A (pl)
CA (1) CA2556383C (pl)
ES (1) ES2392846T3 (pl)
IT (1) ITTO20040124A1 (pl)
NO (1) NO20064426L (pl)
PL (1) PL1727545T3 (pl)
RU (1) RU2377986C2 (pl)
WO (1) WO2005084677A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE515187T1 (de) * 2006-01-19 2011-07-15 Medestea Res & Production S P A Verwendung von n-piperidinderivathaltigen zusammensetzungen zum schutz biologischer systeme
US20090234150A1 (en) * 2006-07-14 2009-09-17 Peter Carmeliet Use of ppar-alpha agonists to treat skeletal muscle wasting disorders
CA2696310A1 (en) * 2007-08-14 2009-02-19 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services, The Method of treating disease involving myelin and/or axonal loss
KR101491763B1 (ko) * 2013-12-19 2015-02-16 대한민국 1-(2-((4-클로로-2-메톡시-5-메칠페닐)아미노)-2-옥소에틸)-ｎ-(2-하이드록시페닐)-피페리딘-4-카복사마이드 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 프리온 질환 예방 및 치료용 약학적 조성물
CN112126060B (zh) * 2019-06-25 2022-05-31 北京天罡助剂有限责任公司 一种聚合型高分子空间位阻胺及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590231A (en) * 1983-10-11 1986-05-20 Ciba-Geigy Corporation Polyolefin compositions stabilized against degradation using hydroxylamine derivatives
US4665185A (en) * 1984-03-22 1987-05-12 Ciba-Geigy Corporation Process for preparing nitroxyls of sterically hindered amines
US4691015A (en) 1984-07-23 1987-09-01 Ciba-Geigy Corporation Hydroxylamines derived from hindered amines
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5036097A (en) * 1989-10-17 1991-07-30 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration
CA2072934C (en) 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5696109A (en) 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
DE69529054T2 (de) 1994-02-28 2003-08-21 Nanopharm Ag System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
EP0709384B1 (de) * 1994-10-31 1998-12-23 MERCK PATENT GmbH Benzylpiperidinderivate mit hoher Affinität zu Bindungsstellen von Aminosäure-Rezeptoren
DE69425287T2 (de) * 1994-11-15 2001-03-15 Moreno Paolini N-hydroxypiperidine als superoxid-radikalfänger
US6420429B1 (en) * 1997-12-23 2002-07-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Brain targeted low molecular weight hydrophobic antioxidant compounds
EP1132085A4 (en) 1998-11-25 2003-04-23 Daiichi Radioisotope Lab MEDICINAL PRODUCTS AND REAGENTS CONTAIN THE N-ACYLOXYLATED CYCLOALKYL COMPOUNDS AS ACTIVE INGREDIENTS
AU2001296984B2 (en) 2000-10-05 2005-08-11 Pharmacia Corporation Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension
EP1353655A2 (en) 2001-01-26 2003-10-22 Metaphore Pharmaceuticals Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
US20050065182A1 (en) 2003-09-23 2005-03-24 Papazoglou Elisabeth S. Method and compositions for chronic wound care
WO2005032479A2 (en) 2003-10-01 2005-04-14 Unviversity Of Florida Research Foundation, Inc. Compositions and methods for selective inhibition of nicotine acetylcholine receptors

Also Published As

Publication number Publication date
NO20064426L (no) 2006-11-29
CA2556383A1 (en) 2005-09-15
RU2006134643A (ru) 2008-04-10
CN1946400A (zh) 2007-04-11
US8461186B2 (en) 2013-06-11
KR20060132746A (ko) 2006-12-21
WO2005084677A1 (en) 2005-09-15
KR101244799B1 (ko) 2013-03-18
ES2392846T3 (es) 2012-12-14
US20070191427A1 (en) 2007-08-16
AU2005218739A1 (en) 2005-09-15
EP1727545A1 (en) 2006-12-06
JP2007525530A (ja) 2007-09-06
RU2377986C2 (ru) 2010-01-10
ITTO20040124A1 (it) 2004-06-01
CN1946400B (zh) 2012-05-09
CA2556383C (en) 2013-05-14
BRPI0507817A (pt) 2007-07-10
EP1727545B1 (en) 2012-08-08

Similar Documents

Publication Publication Date Title
IL187168A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
TWI372146B (en) Imidazole compounds for the treatment of neurodegenerative disorders
IL180680A0 (en) Piperazine derivatives useful for the treatment of gastrointestinal disorders
ZA200706791B (en) Isoxazole combretasin derivatives for the treatment of disorders
PT3424932T (pt) Boronoftalidas para utilização terapêutica
EP1853539A4 (en) HONOKIOL DERIVATIVES TO TREAT PROLIFERATIVE DISEASES
AP2006003671A0 (en) Sulfonamide derivatives for the treatment of diseases
AP2006003669A0 (en) Sulfonamide derivatives for the treatment of diseases
IL177232A0 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
EP1658072A4 (en) Compounds for the Treatment of Neurodegenerative Diseases
AP2006003729A0 (en) Sulfonamide compounds for the treatment of neurodegenerative disorders
IL177455A0 (en) Pyrazoline derivatives useful for the treatment of cancer
ZA200805108B (en) Treatment of neurodegenerative disorders
ZA200802270B (en) Treatment of neurodegenerative disorders
PL1814555T3 (pl) S-mirtazapina do leczenia uderzeń gorąca
PL1727545T3 (pl) Zastosowanie pochodnych N-piperydyny do leczenia patologii neurodegeneracyjnych
EP1750698A4 (en) 5-ANILINO-4-HETEROARYLPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES
PL1879585T3 (pl) Zastosowanie pochodnych pirymidyloaminobenzamidowych do leczenia mastocytozy układowej
GB0519274D0 (en) The treatment of neurodegenerative diseases
ZA200606780B (en) Compounds for the treatment of diseases
ZA200608015B (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
IL177531A0 (en) Compounds for the treatment of diseases
GB0425073D0 (en) Compounds for the treatment of diseases
GB0420867D0 (en) Compounds for the treatment of diseases
AP2008004391A0 (en) Pharmaceutical composition suitable for the treatment of malaris within one day